Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts

G. Price¹, M.K. Brenner¹, H.G. Prentice¹, A.V. Hoffbrand¹, & A.C. Newland²

¹Department of Haematology, Royal Free Hospital, London, NW3; and ²Department of Haematology, The London Hospital, London, E1, UK.

Summary We have studied the cytotoxic effects of recombinant tumour necrosis factor and recombinant gamma interferon on primary cultures of leukaemia cells. The agents were added alone or in a combination to cells from 17 patients. Eleven had acute myeloblastic leukaemia (6 at presentation, 5 at relapse), 4 had acute lymphoblastic leukaemia, one had hairy cell leukaemia, and 2 had chronic myeloid leukaemia – one of whom was in myeloid blast transformation. Cells from patients with lymphoid malignancies or from the patient with chronic phase CML were not affected by either agent in any dose combination. In contrast, reduction of viability of myeloid blasts was weakly accelerated by TNF and γ-interferon individually. Combination of the agents invariably produced enhanced killing and additive or synergistic effects were seen when 20–500 IU ml⁻¹ of each cytokine was present. This sensitivity was also shown by blast cells from 5 patients with relapsed AML. We therefore suggest that trials of such combination therapy may be indicated in drug resistant or relapsed AML.

Two cytokines, tumour necrosis factor (TNF) and γ-interferon (γ-IFN), have been frequently suggested as therapeutic agents for the treatment of malignant disease. TNF was first characterised as a product from activated macrophages that induced regression of some transplanted tumours in rodents (Carswell et al., 1975; Ruff et al., 1980) while having little or no effect on primary cell cultures or normal cell lines. A material with similar properties, lymphotakin, was obtained from mitogen stimulated lymphocytes (Ruddle et al., 1968; Granger et al., 1968) and both agents have subsequently been cloned from human cell lines (Pennica et al., 1984; Gray et al., 1984). It is now clear that in addition to its cytotoxic effects on malignant cells, TNF also regulates the growth of many normal cells – including haemopoietic precursors – by producing reversible suppression of some specific cellular proteins at the level of transcription (Beutler et al., 1985a,b) and by increasing production of others (Kohase et al., 1986). Although TNF effectively destroys some tumour derived lines, others are almost entirely insensitive, and it has been postulated that lack of susceptibility may correlate with low level or absent expression of specific TNF receptors (Tsujimoto et al., 1986; Ruggiero et al., 1986).

Gamma-IFN, like TNF, regulates the growth and differentiation of both normal and malignant cells: it acts to increase synthesis and expression of some proteins, while inhibiting production of others. Although γ-IFN alone inhibits the growth of certain tumours in vitro, its therapeutic effects as a single agent have generally been disappointing (Hawkins, 1986; Bonnem & Spiegel, 1986). However, one of the proteins often induced by γ-IFN is the receptor for TNF, and it has been observed that cell lines with few TNF receptors and which are TNF-insensitive may express increased numbers of TNF receptors and become susceptible to this cytokine when γ-IFN is also present in the culture (Tsujimoto et al., 1986; Ruggiero et al., 1986).

We have now investigated the susceptibility of acute leukaemia blast cells to TNF and γ-IFN alone or in combination. We show that lymphoid leukaemias are generally unaffected by these cytokines, but that myeloid blast cells, including those obtained from patients in relapse, may be highly susceptible to the combination of TNF and γ-IFN, while showing little response to either agent alone. As these cytokines have a mode of action distinct from conventional chemotherapeutic agents, these observations suggest that combination therapy with TNF and γ-IFN should be evaluated in vivo for the treatment of relapsed or resistant myeloid leukaemia.

Materials and methods

Patients and sample collection

Peripheral blood samples from patients with leukaemia were collected in preservative-free heparin. Eighteen patients were studied. Four had ALL, (3 common, 1 T cell), 1 had hairy cell leukaemia and 11 had AML (8 FAB M1 or 2, 1 FAB M4) of whom 6 were untreated and 5 had relapsed after treatment with daunorubicin, cytosine arabinoside and thioguanine. There were 2 patients with CGL, one in first chronic phase (CGL-CP) and 1 with myeloid blast crisis (CGL-BC). Mononuclear cells were isolated by separation over Lymphoprep (Nyegaard) at 400 g for 25 min. All acute leukaemia samples studied had >90% blast cells.

Culture conditions

Cells were grown in RPMI 1640 supplemented with 10% foetal calf serum (FCS), 1-glutamine (2mM), penicillin (100IU ml⁻¹) and streptomycin (100 μg ml⁻¹) at 38°C in 7.5% CO₂, and were cultured in 96 well flat bottom Nunc microculture plates at 2 × 10⁵ cells/100μl.

Cytokines

Recombinant tumour necrosis factor (TNF) (derived originally from a human monocyte cell line and expressed in E.Coli), specific activity 1.5 × 10⁷ IU mg⁻¹ (gift of BASF Knoll, W. Germany) and recombinant (E.Coli) γ-Interferon, specific activity 2.2 × 10⁷ IU mg⁻¹ (γ-IFN gift of Biogen SA, Geneva, Switzerland) were diluted in culture medium and added at concentrations of 20-2000 U ml⁻¹ in a chequerboard pattern (see figure 1). Each combination of cytokines was added to duplicate wells. Cytotoxicity was determined on days 3, 5 and 7 or on days 4 and 7.

Effects of cytokines

Cells from each well were enumerated using a Coulter ZF electronic counter. Cell viability was determined by mixing cells 1:1 (v/v) with 0.5% (w/v) Nigrosin (Sigma) containing 1% (w/v) Fast Green (Sigma). After ten minutes at room
temperature the cells from individual wells were cytocentrifuged onto slides, air dried and fixed with acetone-free methanol before counterstaining with May–Grunwald/Giesma. Two hundred cells were counted on each slide. In preliminary experiments this technique compared well in sensitivity to trypan blue exclusion and had the advantage that the morphology of viable cells could be assessed (Bird et al., 1985).

**Statistical analysis**

Comparison between the effects of different treatments was made by analysis of variance.

**Results**

Cells from all 5 patients with lymphoid malignancies and from the patient with CGL-CP showed no response to the agents alone or in combination. In contrast cells from all 11 patients with AML and from the patient with CGL-BC showed significant responses. Although reduction in viability of AML blasts with time occurred in control cultures, this was only weakly accelerated in the presence of either TNF or γ-IFN alone. However, the combination of TNF and γ-IFN was invariably more effective at inducing cell death. Four patient samples were extremely sensitive and showed between 0 and 5% survival of cells at days 5–7 while control culture viability ranged from 60–90%; even in the least susceptible patient, cell survival was only 34% in the presence of TNF and γ-IFN. Figure 1a,b shows the dose–response effects at day 5 of culture using data from the most susceptible (Figure 1a) and the least susceptible (Figure 1b) cells. γ-IFN alone produced a small but significant effect on viability, while TNF had little effect. At doses between 20 and 200 U of both agents, however, synergy was apparent and this was maximal at 500 U ml⁻¹. Figure 2a,b shows the time course of cell death in these patients, using 500 U ml⁻¹ of TNF and γ-IFN. Cell killing was most rapid in the first 48–96 h but continued to increase up to the 7th day of study. Figure 3 pools data from all 12 patients with AML and compares the mean cell survival between the different treatment groups. Combination therapy in vitro with γ-IFN and TNF clearly has a highly significant effect compared with no treatment (P<0.0001) or with addition of either agent alone (P<0.001).

![Figure 1](image_url)

**Figure 1** Viability of AML cells from (a) good responder; and (b) poor responder at day 5 of culture in the presence of increasing concentrations of TNF/γ-IFN. Blast cells from both donors were obtained at presentation. * = <1% viable cells. TNF dose: □, 0; □, 20; □, 200; □, 500; ■, 2000 U ml⁻¹.

![Figure 2a,b](image_url)

**Figure 2a,b** Time course of cell death of blast cells from good (a) and poor (b) responder illustrated in Figure 1a, b, demonstrating viability of untreated cells and of cells treated with 500 UTNF and 500 U γ-IFN alone or in combination. ■, Control; □, IFN; ○, TNF; ●, TNF & IFN.
Discussion

Recombinant DNA derived cytokines have now been used as single agents in the treatment of a wide variety of tumours. Although some successes have been reported using IL-2 for solid tumours (Ratain et al., 1985) or α-interferon for treatment of hairy cell leukaemia (Rosenberg et al., 1985) and CGL (Talpaz et al., 1985), these agents have generally failed to have limited effects. In part this has been attributed to an intrinsic lack of cell susceptibility, but it is now clear that at least some unresponsive tumours may simply lack appropriate cytokine receptors (Tsujimoto et al., 1985; Ruggerio et al., 1986; Lehmann & Droge, 1986). The observation that γ-IFN induces receptors for TNF on both murine and human tumour cell lines and that the two agents in combination may have synergistic properties (Tsujimoto et al., 1985; Ruggerio et al., 1986), led us to test this combination against a range of fresh leukaemic blasts.

There are two approaches that may be used to evaluate the effect of cytokets on leukaemic blasts. The first is to measure their effects on those cells which form colonies in semi-solid liquid media. This approach has the advantage that it measures activity on a population of growing cells which may also represent clonogenic precursors.

References

ABBoud, S., GerSON, S.L. & BerGER, N.A. (1985). The effect of recombinant human tumour necrosis factor on normal human progenitor cells. Blood, 66 (Suppl 1), 124a.

BUTLER, B., GREENwald, D., HULMES, J.D. & 5 others (1985a). Identity of tumour necrosis factor and the macrophage secreted factor cachectin. Nature, 316, 552.

BEutler, B.A., MilSARK, I.W. & CerAMi, A. (1985a). Cachectin/tumour necrosis factor: Production, distribution and metabolic fate in vivo. J. Immunol., 135, 3972.

BROxMeyer, H.E., WILLIAMS, D.E., Lu, L. & 5 others. (1986). The suppressive influences of human tumor necrosis factors on bone marrow haemopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and Interferon-γ. J. Immunol., 136, 4487.

BIRD, M.C., BOsANquet, A.G. & GIley, E.D. (1985). In vitro determination of tumour chemosensitivity in haematological malignancies. Haematol. Oncol., 3, 1.
BONnen, E.M. & SPIEGEL, R.J. (1987). Phase 1 trials of recombinant gamma interferon. Proceedings of the Fifth NCI-EORTC symposium on new drugs in cancer therapy (in press).

CARSWELL, E.A., OLD, L.S., KASSEL, R.L., GREEN, S., FIORE, N. & WILLIAMSON, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumours. Proc. Natl Acad. Sci., 72, 3666.

GRAY, P.W., AGGARWAL, B.B., BENTON, C.V. & 8 others (1984). Cloning and expression of cDNA for human lymphotxin a lymphokine with tumour necrosis activity. Nature, 312, 721.

KOHASE, M., HENRIKSEN-DeSTEFANO, D., MAY, L.T., VILCEK, J. & SEHGAL, P.B. (1986). Induction of $\beta_2$-Interferon by tumour necrosis factor – a homeostatic mechanism in the control of cell proliferation. Cell, 45, 659.

RATAIN, M.J., GOLOMB, H.M., VARDIMAN, J.W., VOKES, E.E., JACOBS, R.H. & DALY, K. (1985). Treatment of hairy cell leukaemia with recombinant alpha 2 Interferon. Blood, 65, 644.

ROUSENBERG, S.A. & MULE, J.I. (1985). Immunotherapy of cancer with lymphokine activated killer cells and recombinant interleukin-2. Surgery, 98, 437.

RUFF, M.R. & GIFFORD, G.E. (1980). Purification and physico-chemical characterization of rabbit tumour necrosis factor. J. Immunol., 125, 1671.

RUGGERO, V., TAVERNIER, J., Friers, W. & BAGLIONI, C. (1986). Induction of the synthesis of tumour necrosis factor receptors by Interferon $\gamma$. J. Immunol., 136, 2445.

TALPAZ, M., KANTARJIAN, H., McCREDIE, K.B., KEATING, M.J. & GUTTERMAN, J.U. (1985). Chronic myelogenous leukaemia: Haematologic remissions and cytogenetic improvement induced by recombinant Alpha A Interferon. Blood 66 (Suppl. 1), 209a.

TSUJIMOTO, M., YIP, Y.K. & VILCEK, J. (1986). Interferon $\gamma$ enhances expression of cellular receptors for tumour necrosis factor. J. Immunol., 136, 2441.